Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
NovoCure is a commercial-stage oncology company that develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment using low-intensity electric fields. The company's primary approved indication is glioblastoma (GBM), with FDA approval for newly diagnosed and recurrent cases, and has expanded into mesothelioma with EU approval. The stock trades on clinical trial outcomes, regulatory approvals for new indications (particularly non-small cell lung cancer and pancreatic cancer), and adoption rates in existing markets.
NovoCure operates a razor-and-blade model where patients receive TTFields devices on a rental basis while purchasing disposable transducer arrays that must be replaced 2-3 times weekly. Revenue is primarily recurring and subscription-like, with reimbursement from Medicare, private insurers, and international payers. The company has established reimbursement pathways in the US (Medicare covers ~$21,000/month for GBM treatment) and key European markets. Gross margins exceed 75% due to the consumable nature of arrays, but the company remains unprofitable due to heavy R&D spending on pipeline indications and commercial infrastructure buildout. Competitive advantage stems from proprietary electric field delivery technology, extensive clinical data (EF-14 trial showing survival benefit in GBM), and regulatory barriers to entry requiring lengthy clinical trials.
Phase 3 clinical trial readouts for pipeline indications, particularly LUNAR trial (non-small cell lung cancer) and PANOVA-3 (pancreatic cancer)
Regulatory approval decisions from FDA and EMA for label expansions beyond GBM and mesothelioma
Quarterly active patient count growth and net patient additions in core GBM market
Reimbursement coverage decisions from major payers, particularly for new indications
Physician adoption rates and key opinion leader endorsements at major oncology conferences
Clinical trial failure risk for pipeline indications (LUNAR, PANOVA-3) which are critical for growth beyond the limited GBM market (~13,000 US cases annually)
Reimbursement pressure from payers questioning cost-effectiveness versus standard-of-care chemotherapy and immunotherapy combinations
Technological obsolescence risk from emerging cancer treatment modalities including CAR-T, personalized vaccines, and next-generation targeted therapies
Competition from established chemotherapy regimens, immunotherapy combinations (checkpoint inhibitors), and targeted therapies with growing clinical evidence
Physician adoption barriers due to device complexity, patient compliance requirements (18+ hours daily wear time), and preference for traditional systemic therapies
Potential competitive TTFields technologies if core patents (expiring 2027-2034) are challenged or alternative electric field delivery methods emerge
Elevated debt/equity ratio of 2.34 with negative operating cash flow creates refinancing risk if capital markets tighten
Cash burn rate of ~$100M annually (negative FCF) requires continued access to capital markets or debt financing to fund operations and clinical trials
Current ratio of 1.55 provides limited liquidity cushion if revenue growth disappoints or clinical trial costs escalate
low - Cancer treatment demand is non-discretionary and largely insulated from economic cycles. However, hospital capital budgets and physician practice economics can be affected during severe recessions, potentially slowing adoption of new treatment modalities. The company's revenue is primarily driven by clinical outcomes and regulatory approvals rather than GDP growth.
Rising interest rates negatively impact NovoCure through multiple channels: higher cost of capital for a cash-burning growth company (debt/equity of 2.34 suggests meaningful debt service costs), lower valuation multiples for unprofitable biotech/medtech stocks as investors demand higher risk premiums, and potential pressure on hospital system finances affecting technology adoption budgets. The company's negative free cash flow (-$100M) makes it dependent on favorable financing conditions.
Moderate exposure through healthcare system creditworthiness. Revenue depends on timely reimbursement from Medicare, Medicaid, and private insurers. Tightening credit conditions could pressure hospital systems and oncology practices, potentially delaying technology adoption or extending payment cycles. However, the life-saving nature of cancer treatment provides some insulation from credit-driven demand destruction.
growth - The stock attracts biotech/medtech growth investors focused on binary clinical trial outcomes and regulatory catalysts. With negative profitability, high revenue growth (18.8% YoY), and a pipeline-dependent valuation, this is a speculative growth play rather than value or income investment. The 48% one-year decline reflects de-risking after clinical or commercial setbacks. Investors are betting on successful pipeline execution driving multi-billion dollar revenue potential if lung and pancreatic cancer indications gain approval.
high - As a clinical-stage medtech company with binary trial outcomes, the stock exhibits high volatility (evidenced by -48% one-year return). Event-driven volatility around trial readouts, FDA decisions, and quarterly patient count reports is typical. Small market cap ($1.3B) and negative profitability amplify sensitivity to sentiment shifts and sector rotation away from unprofitable growth stocks.
